Abstract:Bcl-2 belongs to a growing family of proteins which regulates programmed cell death (apoptosis). Overexpression of Bcl-2 has been observed in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer. Thereby, Bcl-2 is an attractive new anti-cancer target. Herein, we describe the discovery of novel classes of small-molecule inhibitors targeted at the BH3 binding pocket in Bcl-2. The three-dimensional (3D) structure of Bcl-2 has been modeled on the basis of a high-resolution NMR solution structure of Bcl-X(L), which shares a high sequence homology with Bcl-2. A structure-based computer screening approach has been employed to search the National Cancer Institute 3D database of 206 876 organic compounds to identify potential Bcl-2 small-molecule inhibitors that bind to the BH3 binding site of Bcl-2. These potential Bcl-2 small-molecule inhibitors were first tested in an in vitro binding assay for their potency in inhibition of the binding of a Bak BH3 peptide to Bcl-2. Thirty-five potential inhibitors were tested in this binding assay, and seven of them were found to have a binding affinity (IC(50) value) from 1.6 to 14.0 microM. The anti-proliferative activity of these seven active compounds has been tested using a human myeloid leukemia cell line, HL-60, which expresses the highest level of Bcl-2 protein among all the cancer cell lines examined. Compound 6 was the most potent compound and had an IC(50) value of 4 microM in inhibition of cell growth using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Five other compounds had moderate activity in inhibition of cell growth. Compound 6 was further evaluated for its ability to induce apoptosis in cancer cells. It was found that 6 induces apoptosis in cancer cells with high Bcl-2 expression and its potency correlates with the Bcl-2 expression level in cancer cells. Furthermore, using NMR methods, we conclusively demonstrated that 6 binds to the BH3 binding site in Bcl-X(L). Our results showed that small-molecule inhibitors of Bcl-2 such as 6 modulate the biological function of Bcl-2, and induce apoptosis in cancer cells with high Bcl-2 expression, while they have little effect on cancer cells with low or undetectable levels of Bcl-2 expression. Therefore, compound 6 can be used as a valuable pharmacological tool to elucidate the function of Bcl-2 and also serves as a novel lead compound for further design and optimization. Our results suggest that the structure-based computer screening strategy employed in the study is effective for identifying novel, structurally diverse, nonpeptide small-molecule inhibitors that target the BH3 binding site of Bcl-2.

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

Abstract 2922: Development of Bcl2 BH4 Antagonist for Cancer Therapy

BCL2-BH4 Antagonist BDA-366 Suppresses Human Myeloma Growth

Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy

Abstract 2758: Development of Small Molecule Bax Agonists for Lung Cancer Treatment

Small-molecule Bax Agonists for Cancer Therapy.

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

Abstract 5089: Small Molecule Bax Activator Enhances Immunotherapy Against Lung Cancer

BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Modulation of Bax and Mtor for Cancer Therapeutics

Discovery and optimization of small molecule Bax activators for cancer therapy

Bh4 Domain Of Bcl-2 As A Novel Target For Cancer Therapy

CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth

Abstract 2333: Modulation of Bax and Mtor for Cancer Therapeutics

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

A Deuterated Analog of Dasatinib Disrupts Cell Cycle Progression and Displays Anti‐non‐small Cell Lung Cancer Activity in Vitro and in Vivo

Discovery of Small-Molecule Inhibitors of Bcl-2 Through Structure-Based Computer Screening.

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

A Small-Molecule Inhibitor of Bcl6 Kills Dlbcl Cells in Vitro and in Vivo

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia